Of note, in a recent proof-of-concept study, two patients with systemic lupus erythematosus (SLE) refractory to multiple lines of therapy were successfully treated with anti-CD38 daratumumab, with long-term efficacy that was maintained with belimumab co-administration (33). Here, CD38 is linked to systemic lupus erythematosus.